1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: Results of an interim analysis
    Meeting Abstract

    Brammer, J. E.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Jacobsen, E. D.; Gritti, G.; Litwak, D.; Cohan, D.; Katz, D. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The outcome of CLL patients according to IGHV mutational status: An Israeli perspective
    Meeting Abstract

    Bronstein, Y.; Levi, S.; Tsuriel, S.; Arbel, Y. S.; Joffe, E.; Herishanu, Y.
    Blood (2021)

    Fulltext@MSK | Save
  • MI-IMMUNE/1801: Lessons from an ongoing, multi-center trial involving biospecimen collection for prospective microbiome and immune profiling in patients undergoing reduced intensity conditioning allogeneic HCT
    Meeting Abstract

    Brooks, E.; Spahn, A.; Waldvogel, S.; Howard, A.; Bar, M.; Bratrude, B.; Chhabra, S.; Clark, W.; Das, S. R.; Horowitz, M. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • PK and PD assessment of BET inhibitor pelabresib (CPI-0610) in patients with relapsed or refractory lymphoma: Findings from a phase 1 study
    Meeting Abstract

    Blum, K. A.; Supko, J. G.; Maris, M.; Flinn, I. W.; Goy, A. H.; Younes, A.; Bobba, S.; Senderowicz, A.; Efuni, S.; Rippley, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Multi-recombinase mouse models of FLT3-driven leukemia identifies distinct trajectories of mutational cooperativity and leukemic transformation
    Meeting Abstract

    Bowman, R. L.; Mishra, T.; Eisman, S. E.; Cai, L.; Xiao, W.; Waarts, M. R.; Sanchez Vela, P.; Fernández-Maestre, I.; Csete, I. S.; Potts, C. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A multi-institutional retrospective analysis of T-cell lymphomas with central nervous system relapse
    Meeting Abstract

    Bhansali, R. S.; Ganesan, N.; Stuver, R. N.; Horwitz, S. M.; Wudhikarn, K.; Hwang, S. R.; Bennani, N.; Chavez, J. C.; Sokol, L.; Saeed, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Park, S. I.; Nastoupil, L.; Phillips, T.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Pagel, J. M.; Leonard, J. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in combination with R-CHOP in patients with previously untreated high-risk diffuse large B-cell lymphoma: Preliminary results from a phase 1/2 trial
    Meeting Abstract

    Belada, D.; Christensen, J. H.; Drott, K.; Snauwaert, S.; Brody, J.; Narkhede, M.; Offner, F.; Elliot, B.; Liu, T.; Stirner, M. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1 study of CFT7455, a novel degrader of IKZF1/3, in multiple myeloma and non-Hodgkin lymphoma
    Meeting Abstract

    Berdeja, J.; Ailawadhi, S.; Horwitz, S. M.; Matous, J. V.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Richardson, P. G.; Richard, S.; Bhutani, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study
    Meeting Abstract

    Bartlett, N. L.; Giri, P.; Budde, L. E.; Schuster, S. J.; Assouline, S.; Matasar, M. J.; Yoon, S. S.; Canales, M.; Gutierrez, N. C.; Fay, K.; more...
    Blood (2021)

    Fulltext@MSK | Save